This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Lilly (LLY) Tops Q2 Earnings & Sales, Ups View, Stock Falls
by Zacks Equity Research
Lilly beat estimates for both sales and earnings and raised its 2017 outlook. However, it said the NDA resubmission for its rheumatoid arthritis drug baricitinib will not occur this year.
Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN
by Zacks Equity Research
Three pharma giants are set to report second-quarter results on Jul 25. Let's see how things are shaping up for this quarter.
Merck's Biosimilar Insulin Gets Tentative FDA Approval
by Zacks Equity Research
Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
At Biogen's (BIIB) Q2 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in Q2.
Is a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Cyramza, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Why Did Radius Health (RDUS) Stock Plummet Today?
by Ryan McQueeney
Shares of Radius Health (RDUS) dropped more than 7.8% in early morning trading hours Monday after the company announced that Jesper Hoiland, a former top-ranking executive at Novo Nordisk (NVO), has been appointed its new president and chief executive officer.
Can ImmunoGen's Lead Pipeline Cancer Candidate Boost Growth?
by Zacks Equity Research
On Jul 12, 2017, we issued an updated report on ImmunoGen, Inc. (IMGN).
Lilly Settles Patent Litigation on Cialis with Generic Firms
by Zacks Equity Research
Eli Lilly & Company (LLY) announced that it has entered into an agreement with generic companies to settle a patent relating to its erectile dysfunction drug Cialis (tadalafil).
5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings
by Arpita Dutt
Here is a look at 5 pharma and biotech stocks including Merck (MRK) that are expected to post a positive earnings surprise in Q2.
Lilly's Breast Cancer Drug Gets Priority Review Status by FDA
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that its new drug application for its pipeline candidate, abemaciclib , has been accepted for priority review by the FDA for patients with advanced breast cancer.
Lilly Gets Favorable Ruling in Alimta Patent Lawsuit in UK
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that it has received favorable ruling from the UK Supreme Court in a patent lawsuit against generic drugmaker, Actavis related to its key cancer drug, Alimta (pemetrexed disodium).
Array (ARRY) Submits NDA for Melanoma Combination Therapy
by Zacks Equity Research
Array BioPharma (ARRY) announced that it has submitted two new drug applications (NDAs) to FDA, seeking approval for the combination of binimetinib and encorafenib to treat patients with BRAF-mutant advanced, unresectable or metastatic melanoma.
Sanofi Versus AstraZeneca: Large Cap Pharma Stock Faceoff
by Zacks Equity Research
Both stocks carry a Zacks Rank #2 (Buy).
Merck Falls as FDA Puts Hold on 3 Keytruda Myeloma Studies
by Zacks Equity Research
Merck & Co., Inc. (MRK) shares were down more than 1% in after-hours trading on Wednesday after the company announced that the FDA has placed a clinical hold on three combination studies of Keytruda in multiple myeloma, a form of blood cancer.
Incyte & Lilly's Olumiant Gets Marketing Approval in Japan
by Zacks Equity Research
Incyte Corporation (INCY) and partner Eli Lilly and Company (LLY) announced that arthritis drug Olumiant got approval in Japan.
Alkermes Presents Phase III Data on Schizophrenia Candidate
by Zacks Equity Research
Alkermes plc (ALKS) announced positive preliminary top-line results from a phase III study, ENLIGHTEN-1, evaluating its schizophrenia candidate, ALKS 3831.
Novartis Gets EC Nod for Lung Cancer Drug's Label Expansion
by Zacks Equity Research
Novartis AG (NVS) announced that the European Commission has approved a label expansion of lung cancer drug drug Zykadia.
Alder's Shares Dip Despite Positive Migraine Trial Results
by Zacks Equity Research
Alder Biopharmaceuticals, Inc.'s (ALDR) shares plummeted almost 28% despite the announcement of positive top line results from phase III study, evaluating its lead pipeline candidate eptinezumab for prevention of frequent episodic migraine.
Merck's CETP Inhibitor Reduces CV Risk in Phase III Study
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced that a large late-stage cardiovascular outcomes study (REVEAL) evaluating anacetrapib, a cholesterol-lowering medicine, met the primary endpoint by reducing cardiovascular (CV) risk.
Novartis Cardiovascular Drug Positive, NSCLC Drug Approved
by Zacks Equity Research
Shares of Novartis AG (NVS) were up after the company announced positive top-line results from the global phase III study, CANTOSon cardiovascular drug.
Why You Should Add Novo Nordisk Stock to Your Portfolio
by Zacks Equity Research
Novo Nordisk (NVO) is healthcare company and a with leadership in the global diabetes market. It looks like a great stock to buy now.
Merck's Keytruda on a Roll: Can it Retain the Momentum?
by Zacks Equity Research
As demand for immuno-oncology drugs and their combinations rises, Merck & Co., Inc.'s (MRK) anti-PD-1 therapy, Keytruda, is being touted as a significant top-line driver for this Kenilworth, NJ based pharma giant.
Novo Nordisk's Victoza Gets FDA Panel Nod for Label Expansion
by Zacks Equity Research
Novo Nordisk A/S (NVO) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 17-2 in favor of Victoza that the drug provides substantial evidence of cardiovascular risk reduction in patients with type II diabetes.
5 Reasons Why You Should Invest in AstraZeneca (AZN) in 2017
by Zacks Equity Research
London-based pharma giant, AstraZeneca plc (AZN) has a strong product portfolio and is one of the key players in the global cardiovascular market.
Why Is ImmunoGen (IMGN) Stock Up 131% This Year?
by Zacks Equity Research
Shares of ImmunoGen, Inc. (IMGN) are massively up 130.9% this year so far, outperforming the the Zacks classified Medical-Drugs industry's registered 3.6% increase during this period.